Victory Capital Management Inc. Has $26.35 Million Position in Vericel Co. (NASDAQ:VCEL)

Victory Capital Management Inc. increased its position in shares of Vericel Co. (NASDAQ:VCEL) by 2.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 623,627 shares of the biotechnology company’s stock after buying an additional 12,481 shares during the quarter. Victory Capital Management Inc. owned 1.27% of Vericel worth $26,348,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Swiss National Bank increased its position in shares of Vericel by 0.4% during the first quarter. Swiss National Bank now owns 89,500 shares of the biotechnology company’s stock valued at $4,656,000 after purchasing an additional 400 shares during the period. Sei Investments Co. raised its stake in shares of Vericel by 49.4% in the 1st quarter. Sei Investments Co. now owns 49,340 shares of the biotechnology company’s stock valued at $2,567,000 after buying an additional 16,312 shares in the last quarter. ProShare Advisors LLC lifted its holdings in shares of Vericel by 8.3% during the 1st quarter. ProShare Advisors LLC now owns 12,985 shares of the biotechnology company’s stock worth $675,000 after acquiring an additional 995 shares during the period. State Board of Administration of Florida Retirement System boosted its position in shares of Vericel by 19.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 16,199 shares of the biotechnology company’s stock valued at $843,000 after acquiring an additional 2,600 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Vericel by 1.2% in the first quarter. Vanguard Group Inc. now owns 3,413,442 shares of the biotechnology company’s stock valued at $177,567,000 after acquiring an additional 39,349 shares during the period.

Insider Buying and Selling at Vericel

In other Vericel news, Director Steven C. Gilman sold 5,833 shares of the company’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $41.36, for a total transaction of $241,252.88. Following the transaction, the director now directly owns 11,000 shares in the company, valued at approximately $454,960. This represents a 34.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Dominick Colangelo sold 17,500 shares of Vericel stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total transaction of $724,150.00. Following the sale, the chief executive officer now owns 220,937 shares of the company’s stock, valued at approximately $9,142,373.06. This represents a 7.34 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,166 shares of company stock worth $1,200,764. Insiders own 5.20% of the company’s stock.

Analysts Set New Price Targets

VCEL has been the topic of a number of recent research reports. Stephens lifted their price objective on Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. Canaccord Genuity Group started coverage on Vericel in a report on Friday, August 9th. They set a “buy” rating and a $57.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Vericel in a research report on Friday, November 8th. Finally, Canaccord Genuity Group started coverage on shares of Vericel in a research report on Friday, August 9th. They issued a “buy” rating and a $57.00 price target on the stock. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Vericel presently has a consensus rating of “Moderate Buy” and an average price target of $57.71.

Vericel Stock Down 0.5 %

Shares of NASDAQ VCEL opened at $52.48 on Monday. Vericel Co. has a 12-month low of $32.31 and a 12-month high of $57.81. The firm’s 50-day simple moving average is $44.92 and its 200 day simple moving average is $46.71. The company has a market cap of $2.59 billion, a price-to-earnings ratio of 874.81 and a beta of 1.66.

Vericel (NASDAQ:VCEL) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. The company had revenue of $57.91 million for the quarter, compared to analyst estimates of $55.32 million. Vericel had a net margin of 1.56% and a return on equity of 1.48%. On average, equities analysts expect that Vericel Co. will post 0.13 earnings per share for the current year.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.